FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • February 14th, 2024 • enGene Holdings Inc. • Biological products, (no disgnostic substances) • Delaware
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 13th day of February 2024, by and between enGene Holdings Inc., a corporation existing under the laws of the Province of British Columbia (the “Company”), and the undersigned (“Subscriber” or “you”). The Company and Subscriber are collectively referred to herein as the “Parties,” and each, a “Party.”
enGene USA, Inc. Waltham, Massachusetts 02451 February 13, 2024Transition and Modification Agreement • February 14th, 2024 • enGene Holdings Inc. • Biological products, (no disgnostic substances)
Reference is hereby made to that certain Employment Agreement, dated November 8, 2023 (the “Employment Agreement”), by and between you and enGene USA, Inc., a Delaware corporation (“Company”), which sets forth the terms and conditions of your employment with the Company as the Chief Executive Officer of the Company. Capitalized term used in this letter agreement without definition shall have the meaning ascribed to such terms in the Employment Agreement. The duties and responsibilities of your employment with the Company also include acting as Chief Executive Officer of enGene Holdings, Inc., a corporation incorporated under the laws of British Columbia, Canada and the indirect parent company of the Company (“Parent”).
